Search Results
Your search for this matches 25378 pages
Showing 24801 - 24850Increased Prevalence but Reduced Mortality of Venous Thromboembolism After Major Cancer Surgery
In a study reported in JAMA Surgery, Vincent Q. Trinh, BSc, of the University of Montreal Health Centre, and colleagues assessed trends in incidence and mortality of venous thromboembolism after major cancer surgery in the United States between 1999 and 2009. They found that venous thromboembolism...
Young Breast Cancer Patients With Poorer Financial Status May Experience Delays in Seeking Care
Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...
Statin Use Reduces Cancer-Specific and All-Cause Mortality in Patients With Nonmetastatic Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Oriana Yu, MD, of Jewish General Hospital in Montreal, and colleagues assessed the association of statin use with prostate cancer mortality and all-cause mortality in men with nonmetastatic prostate cancer. They found that postdiagnostic ...
Pegfilgrastim Prophylaxis Throughout Chemotherapy Is More Effective in Preventing Febrile Neutropenia in Breast Cancer (and More Costly)
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
Phase II Trial of Ponatinib Shows Activity in Heavily Pretreated CML and Philadelphia Chromosome–Positive ALL
On October 31, 2013, Ariad Pharmaceuticals, the manufacturer of ponatinib, agreed to an FDA request to suspend marketing and sales of the drug due to the risk of life-threatening blood clots and severe narrowing of blood vessels. The FDA states that it will continue to evaluate ponatinib to further ...
New Mutation Found in the Estrogen Receptor May Cause Resistance to Breast Cancer Treatment
Most patients with estrogen receptor–positive metastatic breast cancer who initially respond to endocrine treatments will eventually develop resistance to the therapies. A study by Ido Wolf, MD, Head of the Oncology Department at the Tel Aviv Sourasky Medical Center in Israel, and colleagues...
Novel Oral Agent Extends Survival in Relapsed/Refractory Colorectal Cancer, Phase II Study Shows
Hopes are high that TAS-102, a novel oral nucleoside agent, will turn out to be an advance in the treatment of advanced colorectal cancer, said Howard Hochster, MD, of the Gastrointestinal Cancer Program at Yale Cancer Center, New Haven, Connecticut, speaking at the Chemotherapy Foundation...
Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia
Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...
Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...
Most Gastroenterologists and Endoscopy Nurses Prefer Propofol Over Moderate Sedation in Screening Colonoscopies, but Would Pay Little Extra for It
Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...
Investigational Anti–PD-1 Immunotherapy Provides Durable Objective Responses in Patients With Previously Treated NSCLC
The investigational anti–PD-1 immunotherapy MK-3475 showed promising objective response rates in patients with previously treated non–small cell lung cancer (NSCLC). The interim data were presented by Edward Garon, MD, Director of Thoracic Oncology at Jonsson Comprehensive Cancer Center ...
FDA Approves Obinutuzumab for Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) today approved obinutuzumab (Gazyva) for use in combination with chlorambucil (Leukeran) to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug with Breakthrough Therapy designation to receive FDA...
One Dose of HPV 16/18 Vaccine Produces Durable Response Against New Infections
Results from the Costa Rica HPV16/18 Vaccine Trial (CVT) has found that 4-year efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle vaccine (Cervarix). The...
Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots
The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...
Teenagers and Young Adults Diagnosed With Cancer Are at Increased Risk of Suicide
Teenagers and young adults are at increased risk of suicide after being diagnosed with cancer, according to a study published today in Annals of Oncology. A study of nearly 8 million Swedes aged 15 and over found that among the 12,669 young people diagnosed with cancer between the ages of 15 and...
Palliative Care Services and Outcomes Improve Using a Standardized Approach
Standardized criteria for initiating palliative care consultations can substantially improve the care of patients with advanced solid tumors, according to research from Mount Sinai School of Medicine, New York, led by Kerin Adelson, MD, Coordinator for Ambulatory Oncology Quality for the Tisch...
Online Training Tool Can Improve Pathway Adherence and Reduce Costs
A new educational tool for oncologists may enhance compliance with quality care standards and improve the value of cancer care, ultimately resulting in big cost savings for health-care systems, according to Karen Fields, MD, and colleagues from H. Lee Moffitt Cancer Center and Research Institute,...
High-Volume Aerobic and Resistance Exercise May Help Reduce Decline in Physical Function During Chemotherapy for Breast Cancer
In a Canadian study reported in the Journal of the National Cancer Institute, Kerry S. Courneya, PhD, of the University of Alberta, and colleagues assessed the impact of different levels of physical exercise on physical functioning in women receiving adjuvant chemotherapy for breast cancer....
Nivolumab Shows Activity in Ipilimumab-Refractory or -Naive Melanoma in Phase I Trial
In a phase I trial reported in the Journal of Clinical Oncology, Jeffrey S. Weber, MD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues assessed the effects of nivolumab—a human immunoglobulin G4-blocking antibody against the T-cell programmed death 1 checkpoint ...
Pemetrexed Improves Progression-Free Survival vs Gefitinib in Second-Line Setting for EGFR Wild-Type Nonsquamous NSCLC
Both pemetrexed (Alimta) and gefitinib (Iressa) are standard second-line treatments for advanced nonsquamous non–small cell lung cancer (NSCLC) in East Asia. In a phase II trial (CTONG 0806) reported at the International Association for the Study of Lung Cancer’s 15th World Conference...
No Progression-Free Survival Difference With First-Line Axitinib vs Sorafenib in Metastatic Renal Cell Carcinoma
In a phase III trial reported in The Lancet Oncology, Thomas E. Hutson, DO, PharmD, of Baylor Sammons Cancer Center and colleagues compared the second-generation VEGFR inhibitor axitinib (Inlyta) with sorafenib (Nexavar) as first-line treatment of metastatic renal cell carcinoma. There was no...
Long-Distance Travel for Cancer Care Is Linked to Later-Stage Breast Cancer Diagnosis
The longer a woman with breast cancer has to travel to reach a comprehensive cancer center, the more likely she is to have later-stage disease at diagnosis, and the more likely she is to have a mastectomy, according to study by medical student Krishan Jethwa and colleagues from the University of...
Prolonged Sedentary Behavior Linked to Recurrence of Precancerous Colorectal Tumors in Men
Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention...
African American Women Are Less Likely to Benefit From HPV Vaccines for Cervical Cancer Prevention
Vaccines currently available to prevent the two most common strains of human papillomavirus (HPV), HPV 16 and 18, responsible for about 70% of cervical cancers, may not be protective in African American women, according to a study by Cathrine Hoyo, PhD, MPH, Associate Professor in the Obstetrics...
Shortened Telomeres in Blood Leukocytes May Be Associated With Increased Risk of Aggressive Prostate Cancer
Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...
New Biomarker May Differentiate Progressive From Nonprogressive Ductal Carcinoma in Situ
Measuring the presence and amount of the protein Vav2 may help identify breast precancers that will progress to invasive cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held October 27 to 30 in National Harbor,...
Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
Urologist Ownership of Intensity-Modulated Radiation Therapy Services Significantly Increases Use of Treatment for Prostate Cancer
In a study reported in The New England Journal of Medicine, Jean M. Mitchell, PhD, of Georgetown University, examined patterns of use of intensity-modulated radiation therapy to treat prostate cancer among urologists in private practice who have integrated intensity-modulated radiation therapy into ...
FDA Approves First Extended-Release, Single-Entity Hydrocodone Product
The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate extended-release capsules (Zohydro ER) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. The drug, a Schedule ...
Complete Sequencing of All Known Breast Cancer Genes Explains Occurrence of the Cancer in Women With Normal BRCA Genes
Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2, and the vast majority of those patients were told that their gene sequences were normal. With the development of modern genomics...
Novel Gene-Diet Interaction May Explain Association Between Red and Processed Meat Consumption and Colorectal Cancer Risk
A newly discovered potential gene-diet interaction for colorectal cancer may shed light on the statistically significant increased risk of colorectal cancer that is associated with consumption of red and processed meat, according to a study reported yesterday at the American Society of Human...
Study Clarifies Value—and Limitations—of Patient Assistance Programs for Women With Breast Cancer
Patient assistance programs can help patients with breast cancer meet a variety of needs that might otherwise interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of...
Bone Marrow Transplant Linked to Negative Sexual Side Effects in Both Men and Women
New research ties preparative procedures and complications associated with blood or bone marrow transplant with diminished sexual health in both men and women who have undergone the procedure. Study data, published today in Blood, confirm chronic graft-vs-host disease as a potential source of...
Combining Metformin With Chemotherapy and Radiation May Improve Outcomes in Lung Cancer Patients
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggested new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings will be presented by...
Report of Pancreatic Atrophy in Two Patients Receiving Long-Term Sorafenib
In a letter to The New England Journal of Medicine, Ségolène Hescot, MD, of Université Paris Descartes, and colleagues reported evidence of irreversible pancreatic atrophy in two patients after long-term sorafenib treatment. Both patients received cumulative doses of sorafenib...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
Addition of Nab-Paclitaxel to Gemcitabine Improves Survival in Previously Untreated Metastatic Pancreatic Cancer
In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) to gemcitabine in patients with previously untreated...
New Biomarker May Help Guide Treatment of Melanoma Patients
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...
New Molecular Diagnostics Platform Enables Rapid Detection of BRAF V600 Mutations
A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented at the AACR-NCI-EORTC International...
FDA Grants Priority Review to Ramucirumab as a Potential Single-Agent Treatment for Advanced Gastric Cancer
The U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. Ramucirumab is a human monoclonal antibody that...
Phase II Study Supports Axitinib Dose Titration in Select Treatment-Naive Metastatic Renal Cell Carcinoma Patients
Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic, and colleagues evaluated the effects of axitinib dose titration in...
Robust Activity Shown for Investigational PARP Inhibitor BMN673 in BRCA-Related Cancers
In patients with heavily pretreated advanced BRCA-related breast and ovarian cancers, the investigational poly (ADP-ribose) polymerase (PARP) inhibitor BMN673 produced an objective response rate of more than 40% and delayed disease progression by more than 6 months, according to a multicenter phase ...
Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
Imatinib Rechallenge Slows Disease Progression in Patients With Metastatic or Unresectable GIST After Imatinib and Sunitinib
In the RIGHT trial, reported in The Lancet Oncology, Yoon-Koo Kang, MD, of University of Ulsan College of Medicine in Seoul, and colleagues assessed the effects of imatinib (Gleevec) rechallenge in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) after objective...
Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...
Novel Drug Combinations Targeting Pathways Triggered by KRAS May Benefit Patients With Pancreatic Cancer
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented at the AACR-NCI-EORTC...
New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment
The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...
Targeted Investigational Therapy Has Potential to Overcome Crizotinib Resistance in Lung Cancers
The investigational drug PF-06463922 may have the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results (Abstracts A277, PR10/B107, and C253) presented at the AACR-NCI-EORTC International Conference on...
Potential New Drug Effective in Breast Cancer and Melanoma Resistant to Targeted Therapies
LEE011, an investigational small-molecule inhibitor of cyclin-dependent kinase (CDK) 4/6, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, according to findings presented at the AACR-NCI-EORTC...
Investigational EGFR Inhibitor May Hold Promise for Some Patients With Treatment-Resistant NSCLC
Approximately 50% of non–small cell lung cancer (NSCLC) patients who develop resistance to inhibitors of the epidermal growth factor receptor (EGFR) have acquired a second mutation, T790M, which no current EGFR inhibitors target. This may change if the AstraZeneca investigational compound...
